Jemperli

Dostarlimab, the active ingredient in Jemperli, is a PD‑1 inhibitor presented as an injection solution for infusion for intravenous use. It is indicated for mismatch repair deficient (dMMR) endometrial cancer and other dMMR/MSI‑H solid tumors in adult patients.

GNH USA supplies Jemperli as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic medicines. Its network reaches hospitals, oncology centres, and pharmacies across Europe, Asia, Africa and the Americas.

Jemperli targets tumors with deficient mismatch repair or high microsatellite instability, providing an immunotherapy option for several cancer types.

- Mismatch repair deficient (dMMR) endometrial cancer: improves progression‑free survival in patients with advanced disease. - dMMR/MSI‑H solid tumors: offers a treatment alternative for tumors that exhibit high microsatellite instability. - Advanced solid tumors with dMMR/MSI‑H after prior therapy: provides therapeutic benefit when other options have been exhausted.

Jemperli may cause a range of immune‑related adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness that may affect daily activities. - Nausea: upset stomach often accompanied by the urge to vomit. - Diarrhea: loose, frequent stools. - Infusion‑related reactions: flushing, chills, or shortness of breath during administration. - Rash: skin redness or irritation. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Immune‑mediated pneumonitis: inflammation of lung tissue that can impair breathing. - Colitis: inflammation of the colon causing severe diarrhea and abdominal pain. - Hepatitis: liver inflammation that may elevate liver enzymes. - Endocrinopathies: disorders of thyroid, adrenal or pituitary glands. - Severe infusion reactions: anaphylaxis or hypotension. - Myocarditis: inflammation of heart muscle that can affect cardiac function.

Before initiating Jemperli, clinicians should consider several safety precautions to minimize risks.

- Monitor for immune‑related adverse events: watch for signs of pneumonitis, colitis, hepatitis, and endocrinopathies. - Assess baseline organ function: evaluate liver, kidney and thyroid status prior to treatment. - Avoid live vaccines during therapy: immunosuppression may increase infection risk. - Pregnancy and breastfeeding: safety unknown; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jemperli can interact with other agents that affect immune function or increase toxicity.

Major Interactions (Avoid): - Concomitant use with other PD‑1/PD‑L1 inhibitors: additive immune‑related toxicity. - Live vaccines: contraindicated due to impaired immune response.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may blunt therapeutic effect, monitor disease response. - Anticoagulants: monitor for bleeding if infusion reactions occur. - Drugs affecting liver enzymes: observe for altered metabolism of concomitant medications.